Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8TF40
UPID:
FNIP1_HUMAN
Alternative names:
-
Alternative UPACC:
Q8TF40; D6RJH5; Q86T47; Q9BUT0
Background:
Folliculin-interacting protein 1 plays a pivotal role in cellular processes, including amino acid sensing, mTORC1 signaling, and autophagy. It acts as a binding partner for the GTPase-activating protein FLCN, regulating the MiT/TFE factors and promoting FLCN recruitment to lysosomes. Additionally, it serves as a co-chaperone of HSP90AA1/Hsp90, influencing the activity of kinase and non-kinase client proteins.
Therapeutic significance:
Linked to Immunodeficiency 93 and hypertrophic cardiomyopathy, Folliculin-interacting protein 1's involvement in critical cellular pathways underscores its potential as a target for therapeutic intervention. Understanding its role could open doors to novel treatments for related disorders.